EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Ultrasensitive and Multiple Biomarker Discrimination for Alzheimer's Disease via Plasmonic & Microfluidic Sensing Technologies

Lijiao Zu, Xicheng Wang, Peng Liu, Jiwei Xie, Xuejun Zhang, Weiru Liu, Zhencheng Li, Shiqing Zhang, Kaiwei Li, Ambra Giannetti, Wei Bi, Francesco Chiavaioli iD und 2 weitere

Advanced Science · 2024

DOI: 10.1002/advs.202308783 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Advanced Science, 2024. Verfasst von Lijiao Zu und 13 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Photonics Technology, Jinan University, Guangzhou, 510632, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Biomarkers, Amyloid beta-Peptides, Biosensing Techniques. Die Arbeit wurde bisher 57-mal zitiert (Crossref) und nennt 72 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the National Natural Science Foundation of China, the Guangdong Outstanding Scientific Innovation Foundation, the Program of Marine Economy Development Special Fund under Department of Natural Resources of Guangdong Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As the population ages, the worldwide prevalence of Alzheimer's disease (AD) as the most common dementia in the elderly is increasing dramatically. However, a long‐term challenge is to achieve rapid and accurate early diagnosis of AD by detecting hallmarks such as amyloid beta (Aβ 42 ). Here, a multi‐channel microfluidic‐based plasmonic fiber‐optic biosensing platform is established for simultaneous detection and differentiation of multiple AD biomarkers. The platform is based on a gold‐coated, highly‐tilted fiber Bragg grating (TFBG) and a custom‐developed microfluidics. TFBG excites a high‐density, narrow‐cladding‐mode spectral comb that overlaps with the broad absorption of surface plasmons for high‐precision interrogation, enabling ultrasensitive monitoring of analytes. In situ detection and in‐parallel discrimination of different forms of Aβ 42 in cerebrospinal fluid (CSF) are successfully demonstrated with a detection of limit in the range of ≈30–170 pg mL −1 , which is one order of magnitude below the clinical cut‐off level in AD onset, providing high detection sensitivity for early diagnosis of AD. The integration of the TFBG sensor with multi‐channel microfluidics enables simultaneous detection of multiple biomarkers using sub‐µL sample volumes, as well as combining initial binding rate and real‐time response time to differentiate between multiple biomarkers in terms of binding kinetics. With the advantages of multi‐parameter, low consumption, and highly sensitive detection, the sensor represents an urgently needed potentials for large‐scale diagnosis of diseases at early stage.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alzheimer DiseaseBiomarkersAmyloid beta-PeptidesBiosensing TechniquesHumansMicrofluidicsSurface Plasmon ResonanceMicrofluidic Analytical TechniquesEarly Diagnosis

Stichwörter der Autor:innen

Alzheimer's diseasemicrofluidicsmonomer and oligomer of Aβ42surface plasmon resonancetilted fiber Bragg grating

Substanzen

BiomarkersAmyloid beta-Peptides

Autor:innen und Institutionen

  • Institute of Photonics Technology, Jinan University, Guangzhou, 510632, China.
  • State Key Laboratory of Bioactive Molecules and Druggability Assessment, JNU-HKUST Joint Laboratory for Neuroscience and Innovative Drug Research, College of Pharmacy, Jinan University, Guangzhou, 510632, China.
  • Center for Advanced Biomedical Imaging and Photonics, Division of Gastroenterology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard University, Boston, 02215, USA.
  • National Research Council of Italy (CNR), Institute of Applied Physics "Nello Carrara" (IFAC), Sesto Fiorentino, 50019, Italy.
  • Department of Neurology, The First Affiliated Hospital of Jinan University, Guangzhou, 510632, China.

ORCID-Profile: Francesco Chiavaioli, Lei Shi, Tuan Guo

Förderung

  • the National Natural Science Foundation of China
  • the Guangdong Outstanding Scientific Innovation Foundation
  • the Program of Marine Economy Development Special Fund under Department of Natural Resources of Guangdong Province
  • the Guangdong Basic and Applied Basic Research Foundation
  • the International Science and Technology Cooperation Projects of Guangdong Province
  • the Science and Technology Key Project of Guangdong Province
  • the Clinical Frontier Technology Program of the First Affiliated Hospital of Jinan University, China
  • the Science and Technology Projects in Guangzhou

Zitieren

APA

Zu, L., Wang, X., Liu, P., Xie, J., Zhang, X., Liu, W., Li, Z., Zhang, S., Li, K., Giannetti, A., Bi, W., Chiavaioli, F., Shi, L., & Guo, T. (2024). Ultrasensitive and Multiple Biomarker Discrimination for Alzheimer's Disease via Plasmonic & Microfluidic Sensing Technologies. Advanced Science. https://doi.org/10.1002/advs.202308783

Vancouver

Zu L, Wang X, Liu P, Xie J, Zhang X, Liu W, et al. Ultrasensitive and Multiple Biomarker Discrimination for Alzheimer's Disease via Plasmonic & Microfluidic Sensing Technologies. Advanced Science. 2024. doi:10.1002/advs.202308783

BibTeX
@article{Zu2024,
  author = {Zu, Lijiao and Wang, Xicheng and Liu, Peng and Xie, Jiwei and Zhang, Xuejun and Liu, Weiru and Li, Zhencheng and Zhang, Shiqing and Li, Kaiwei and Giannetti, Ambra and Bi, Wei and Chiavaioli, Francesco and Shi, Lei and Guo, Tuan},
  title = {Ultrasensitive and Multiple Biomarker Discrimination for Alzheimer's Disease via Plasmonic & Microfluidic Sensing Technologies},
  journal = {Advanced Science},
  year = {2024},
  doi = {10.1002/advs.202308783}
}
Kostenlos starten →